Chronic Graft-Versus-Host Disease and Disease Status at Relapse as Predictors of Clinical Outcomes in Patients Receiving Azacitidine & Donor Lymphocyte Infusions as Salvage Therapy for Post Allograft Relapse of Myeloid Neoplasms

Background: Azacitidine (Aza) and donor lymphocyte infusions (DLI) confer survival advantage with improved tolerability for patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) following allogenic stem cell transplantation (SCT).

Source: Biology of Blood and Marrow Transplantation - February 1, 2018 Category: Hematology Authors: John Preston Claiborne, Catherine H. Roberts, Kelly G. Hawks, Dipankar Bandyopadhyay, Gary Lee Simmons, Christina M. Wiedl, Harold M. Chung, William B. Clark, John M. McCarty, Amir A. Toor Source Type: research